Results 91 to 100 of about 22,236,668 (323)

Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab.

open access: yesThe Journal of the National Comprehensive Cancer Network, 2020
BACKGROUND Immune-related adverse events (irAEs) are known to occur in patients with cancer who are treated with immune checkpoint inhibitors. However, limited literature exists on the incidence, time of onset, and risk factors for irAEs, particularly ...
G. Kichenadasse   +5 more
semanticscholar   +1 more source

Treatment-related adverse events occurring in ≥1% of the total population (SS).

open access: yes, 2018
Treatment-related adverse events occurring in ≥1% of the total population (SS).
Lionel Noah (6095636)   +7 more
core   +1 more source

Number of Subjects with Related Treatment-Emergent Adverse Events by System Organ Class and Preferred Term.

open access: yes, 2022
Number of Subjects with Related Treatment-Emergent Adverse Events by System Organ Class and Preferred Term.
Matthew Duchars (8713179)   +12 more
core   +1 more source

Abatacept for Prophylaxis of Acute and Chronic Graft‐Versus‐Host‐Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation—A Systematic Review and Meta‐Analysis of Cohort Studies

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Graft‐versus‐host disease (GvHD) remains one of the most significant complications of hematopoietic stem cell transplantation (HSCT). Abatacept, a selective T‐cell costimulation modulator, is a relatively novel prophylactic agent, though pediatric data remain limited.
Matthijs D. Kruizinga   +3 more
wiley   +1 more source

Liposomal Amphotericin-B Infusion-related Reactions and Rate of Infusions: A Single Center Cohort Study

open access: yesJournal of Microbiology and Infectious Diseases, 2022
Objectives: Liposomal amphotericin B is a broad-spectrum antifungal treatment used for life-threatening infections, but it commonly induces infusion-related adverse events that may prevent treatment completion.
Iouri Banakh   +2 more
doaj   +1 more source

Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation [PDF]

open access: yesHealth and Quality of Life Outcomes, 2008
Abstract Objective To examine the impact of schizophrenia, its treatment and treatment-related adverse events related to antipsychotics, on quality of life from the perspective of schizophrenia patients and laypersons.
Reaney Matthew   +6 more
openaire   +3 more sources

Treatment reactions and adverse events possibly related to the treatment.

open access: yes, 2016
Treatment reactions and adverse events possibly related to the treatment.
Guoyu Zhou (3167277)   +13 more
core   +1 more source

Bone and Soft Tissue Neoplasms in Infants Versus Older Children: A Report From the Cancer in Young People in Canada Program

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims Infant bone and soft tissue neoplasms present distinct clinical challenges and lack large‐scale data to inform treatment decisions. This study aims to characterize bone and soft tissue neoplasms in infants in Canada and to compare their outcomes with those of older pediatric patients.
Samuel Sassine   +21 more
wiley   +1 more source

Impact of Initial Treatment Setting on Survival in Relapsed Pediatric and AYA Bone Sarcomas: A Secondary Analysis of a Prospective Clinical Trial

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Outcomes in relapsed or refractory pediatric and AYA bone sarcomas remain poor, and the impact of early referral to specialized sarcoma centers on survival is unclear. Early centralization of care may improve local and systemic treatment quality, but evidence in this population is limited.
Justyna Antoniuk‐Majchrzak   +9 more
wiley   +1 more source

Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes

open access: yesRadiology and Oncology, 2021
Immunotherapy with CTLA-4 inhibitors and PD1 checkpoint inhibitors has initiated a breakthrough in the treatment and prognosis of patients with metastatic melanoma. The survival of these patients has increased from the expected survival time of less than
Mesti Tanja   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy